BioHarvest Sciences Inc. files Form 6-K current reports as a foreign issuer, with exhibits that document company announcements and material changes. These filings cover the company's Botanical Synthesis platform, its VINIA-branded nutraceutical products, CDMO activities for plant-based compounds, earnings-call announcements, and business updates.
The filing record also includes governance and capital-structure subjects such as board composition changes, executive leadership transitions, long-term incentive awards, stock options, restricted share units, and equity incentive plan activity. Together, the disclosures provide formal records of BioHarvest's operating focus, public-company governance, compensation structure, and recurring communications to the market.
BioHarvest Sciences reported first quarter 2026 revenue of $8.5 million, up 8% year over year, with gross margin improving to 59% from 58%. The business is managed through a CDMO services segment and a direct-to-consumer products segment.
Operating loss was $1.8 million, slightly wider than last year, and net loss was $2.6 million, or $0.11 per share. Adjusted EBITDA loss held roughly flat at $1.2 million, reflecting continued investment in growth rather than profitability.
On the CDMO side, BioHarvest advanced two Botanical Synthesis programs to Stage 2, with combined agreements valued at over $2 million, including a $1.2 million fragrance contract and a saffron program valued at over $1 million. On the D2C side, the VINIA brand reached 90,000 active users and its Blood Flow Hydration product generated $920,000 in cumulative revenue since launch, supported by a shift from TV to digital marketing. Cash and bank deposits totaled $20.2 million as of March 31, 2026.
BioHarvest Sciences Inc. reported Q1 2026 revenue of $8,507 thousand, up from $7,860 thousand a year earlier, driven mainly by its Products unit and strong CDMO services growth. Gross margin was about 59%, similar to last year, but the company still posted a net loss of $2,641 thousand, slightly larger than the prior period.
Cash and cash equivalents were $19,167 thousand as of March 31, 2026, giving positive working capital of $18,742 thousand. Management nonetheless discloses that recurring losses, ongoing investment needs and reliance on future financing raise substantial doubt about the company’s ability to continue as a going concern, even though they believe current resources support operations for at least the next 12 months.
BioHarvest Sciences Inc. has appointed Nedira Salzman-Frenkel as Vice President of Business Development for its contract development and manufacturing organization (CDMO) division. Her role focuses on sourcing and managing new contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic markets as the company grows this business.
The company states that Salzman-Frenkel will work closely with senior leadership to help deliver revenue targets and support the launch of a new facility next year. Her background includes senior business development roles in biotech and contract research, where she previously secured substantial CRO contracts and licensing arrangements.
BioHarvest Sciences Inc. reported that its CDMO division has successfully completed Stage 1 of a multi-stage saffron development agreement valued at $1.125 million. Stage 1 established a stable saffron cell bank with key bioactive compounds for potential nutraceutical and culinary uses.
Completion of Stage 1 triggers progression to Stage 2, which will use the company’s Botanical Synthesis™ platform in bioreactors to generate biomass for pre-commercial testing and product development. BioHarvest retains a 25% ownership interest in the saffron composition and is entitled to future manufacturing royalties on any saffron compounds produced using its platform.
BioHarvest Sciences Inc. reported that its CDMO division has signed a $1.2 million Stage 2 contract to develop a rare fragrance ingredient using its proprietary Botanical Synthesis platform. The source plant is described as one of the most valuable fragrance raw materials globally, with premium grades selling for tens of thousands of dollars per kilogram.
Stage 2 follows completion of Stage 1 in March 2026, when a stable cell bank containing rare molecules was created. Over the next six to nine months, BioHarvest aims to produce enough fragrance raw material for commercial trials. Under the agreement, the company retains 20% ownership of successfully developed compositions and is positioned as the manufacturing entity, supporting a long-term, royalty-driven economic model.
Management highlighted that this milestone advances BioHarvest toward potential production in the second half of 2027, aligned with a planned new production facility. The company links this opportunity to an estimated $23 billion premium fragrance segment within a $58.9 billion global scents and fragrances market.
BioHarvest Sciences Inc. has announced a strategic leadership transition focused on its direct-to-consumer and CDMO businesses. Co-founder and Executive Chairman Dr. Zaki Rakib has assumed the role of Chief Executive Officer, unifying leadership of R&D, manufacturing, and operations under a single structure.
Former CEO Ilan Sobel, who led the company from pre-revenue to approximately $35 million in revenue in fiscal year 2025, has stepped down from his executive role and joined the Board of Directors to concentrate on advancing the D2C business. The board highlighted Dr. Rakib’s more than 35 years of executive experience, his deep knowledge of BioHarvest’s technology platform, and his track record building high-growth companies, including scaling Terayon Communication Systems to $380 million in annual revenue and a $7 billion market capitalization as a Nasdaq-listed company.
BioHarvest Sciences Inc. filed a Form 6-K announcing it will release its first quarter 2026 financial results before the market opens on May 14, 2026. The company will hold a conference call and live webcast at 8:00 a.m. U.S. Eastern Time to review results and provide a business update.
BioHarvest describes itself as a leader in Botanical Synthesis, using a patented platform to grow plant-based compounds without cultivating the full plant. It operates as a CDMO for novel plant-based compounds and develops proprietary nutraceutical health and wellness products, including dietary supplements.
BioHarvest Sciences Inc. announced a strategic leadership transition, with Co-Founder and Executive Chairman Dr. Zaki Rakib assuming the role of Chief Executive Officer to lead its Contract Development and Manufacturing Organization (CDMO), integrating R&D, manufacturing, and operations under unified leadership.
Former CEO Ilan Sobel, who has led the company since 2020, has joined the Board of Directors with a focused mandate to advance the direct-to-consumer (D2C) business, including expanding the VINIA brand beyond online channels. Under his tenure, BioHarvest grew from pre-revenue to approximately $35 million in revenue in fiscal year 2025 and built a base of more than 85,000 VINIA consumers in the USA.
The company highlights Dr. Rakib’s more than 35 years of executive experience and prior success scaling Terayon Communication Systems to $380 million in annual revenue and a $7 billion market capitalization as context for his role in driving BioHarvest’s next growth phase across its CDMO and nutraceutical businesses.
BioHarvest Sciences Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing states the registrant had 22,666,842 common shares issued and outstanding as of December 31, 2025. The report incorporates the AIF, audited consolidated financial statements, MD&A and governance documents as exhibits.
The filing notes the Company is a foreign private issuer, prepares financial statements under IFRS, and did not include management's internal control attestation due to the SEC transition period for newly public companies.
BioHarvest Sciences Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing states the registrant had 22,666,842 common shares issued and outstanding as of December 31, 2025. The report incorporates the AIF, audited consolidated financial statements, MD&A and governance documents as exhibits.
The filing notes the Company is a foreign private issuer, prepares financial statements under IFRS, and did not include management's internal control attestation due to the SEC transition period for newly public companies.
BioHarvest Sciences reports that its VINIA nutraceutical line has become the #1 resveratrol polyphenol brand in the United States, based on 2025 sales versus NielsonIQ and Amazon market projections. VINIA’s position is tied to clinically demonstrated increases in arterial dilation, which improve blood flow and oxygen delivery.
The direct‑to‑consumer VINIA business generated more than $30 million in U.S. revenue for full‑year 2025 and about $85 million in global cumulative revenue to date, with roughly 80% of U.S. VINIA revenue coming through the VINIA.com website. BioHarvest cites over 85,000 active users across the United States and Israel.
The company highlights its proprietary Botanical Synthesis platform, which grows a red grape cell composition that can magnify piceid resveratrol levels by up to 100x versus natural grapes while preserving a complex of grape polyphenols. Management positions VINIA as a foundational compound for future plant‑based health products.